DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Rubius Therapeutics Q4 EPS $(0.56) Beats $(0.6) Estimate

Rubius Therapeutics (NASDAQ:RUBY) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.6) by 6.67 percent. This is a 60 percent decrease over losses of $(0.35) per share from

Benzinga · 03/12/2020 11:11

Rubius Therapeutics (NASDAQ:RUBY) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.6) by 6.67 percent. This is a 60 percent decrease over losses of $(0.35) per share from the same period last year.